"We have resolved many of the differentiators in genetics, by shifting our focus to non-coding regulatory genes, the epigenome, and the spatial genome."
The Science Behind Pharmacophenomics
A New Paradigm
PHI's technology and products are based on a new paradigm of gene regulation in which spatial genome and epigenome networks play a prominent role. In this paradigm, transcription is the result of the convergence of a series of spatial and functional factors that take place at the union of gene promoters with controlling enhancers and co-regulated genes in a transcription factory. These factories assemble prior to the initiation of transcription with the aid of activating 3D transcription factors and epigenomic marks in a cell-specific manner, with some enhancers active in different or multiple cell types.
Spatial contacts between regulatory elements, such as enhancers and promoters, occur in space and time (the 4D nucleome), resulting in molecular networks that exhibit both plasticity and adaptability. The powerful role played by circadian rhythm in drug response and medication efficacy also provides the basis for optimizing precision and personalized medicine.
Research in the 3D and 4D network of drug mechanisms has shown that they share many components with disease networks. This intimate relationship extends not only to molecules within a specific pathway, but to individual variants associated with treatment response stratification. Spatial networks and pathways containing disease risk, drug response, and adverse event variants form the foundations for PHI's technology, products, and services.